Vutrisiran
Full Prescribing Information for AMVUTTRA® (vutrisiran)
Explore a range of clinical and educational resources related to the use of vutrisiran in patients with the polyneuropathy of ATTRv (also known as hATTR) amyloidosis.
If you require any further information on vutrisiran, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.
More Information
For more information about data regarding vutrisiran, please visit our Congresses and Publications resources page.
HELIOS-A: Efficacy and safety of vutrisiran in patients with hATTR with polyneuropathy
Summary of the efficacy and safety results of vutrisiran compared to external placebo for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy, as published in the journal Amyloid, 2022.
Insights from the HELIOS-A Study
This deck highlights data from the Phase 3 HELIOS-A trial of vutrisiran in patients with hATTR-PN.
Slide Deck
